Attilio Olivieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Attilio Olivieri has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Saraceni
Hematology, SCT and Cellular Therapy, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy
4 shared publications - Michele Malagola
Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
4 shared publications Cristina Skert
23Department of Molecular Biotechnology, University of Turin, Torino, Italia
3 shared publications- Massimo Martino
Hematology and Stem Cell Transplantation and Cellular Rerapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Presidio Morelli, 89121 Reggio Calabria, Italy
3 shared publications - Mirko Farina
Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
3 shared publications - Nicola Polverelli
Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7771-7774
A curative-intent treatment program in older AML: mature posttransplant results from the VEN-DEC GITMO study
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7771-7774
A curative-intent treatment program in older AML: mature posttransplant results from the VEN-DEC GITMO study
- 2 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1-9
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients
Two hundred and fifty-eight patients with newly diagnosed cGVHD have been enrolled in a multicenter study (NCT02991846). Primary endpoint was failure free survival (FFS); secondary endpoints were ORR at 6 and 12 months after best available therapy (BAT) and OS. Response evaluation was supported by a software (Crosy) collecting cGvHD master data. Software-assisted (SA) response and clinician-based (CB) evaluation, according to NIH criteria, have been performed in parallel at 6 and 12 months. Among 258 patients, 200 needed systemic therapy (ST); 167 were evaluable for response; ORR according to SA was 62% (CR:19%; PR: 43%), and 65% (CR: 23%; PR: 42%) according to the CB evaluation; overall agreement was 66%. In multivariate analysis, only 6-month SA response significantly predicted OS, being more effective in capturing Mixed Responses, compared to CB evaluation. After 12 months 23% of patients were able to stop ST: significantly more patients who maintained ST1 stopped ST (39%) than those who requested a ST1 change (9,5%); (p < 0.001). The 2-year FFS of patients receiving ST was 67%; 2-year OS was 85%: 32 patients (18%) died (30 due to cGVHD progression or causes coexisting with cGvHD). SA evaluation of response in cGVHD is reliable and predicts FFS.
- 2 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1-9
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients
Two hundred and fifty-eight patients with newly diagnosed cGVHD have been enrolled in a multicenter study (NCT02991846). Primary endpoint was failure free survival (FFS); secondary endpoints were ORR at 6 and 12 months after best available therapy (BAT) and OS. Response evaluation was supported by a software (Crosy) collecting cGvHD master data. Software-assisted (SA) response and clinician-based (CB) evaluation, according to NIH criteria, have been performed in parallel at 6 and 12 months. Among 258 patients, 200 needed systemic therapy (ST); 167 were evaluable for response; ORR according to SA was 62% (CR:19%; PR: 43%), and 65% (CR: 23%; PR: 42%) according to the CB evaluation; overall agreement was 66%. In multivariate analysis, only 6-month SA response significantly predicted OS, being more effective in capturing Mixed Responses, compared to CB evaluation. After 12 months 23% of patients were able to stop ST: significantly more patients who maintained ST1 stopped ST (39%) than those who requested a ST1 change (9,5%); (p < 0.001). The 2-year FFS of patients receiving ST was 67%; 2-year OS was 85%: 32 patients (18%) died (30 due to cGVHD progression or causes coexisting with cGvHD). SA evaluation of response in cGVHD is reliable and predicts FFS.
- Open Access
- 24 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1176-1181
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first complete remission
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and efficacy of FT14 conditioning regimen in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in first complete remission.(EudraCT Number:2021-006515-28; Clinical trial number NCT07232953). The study was designed to provide a non-inferior alternative to standard busulfan-containing regimens, which would enable effective transplantation while minimizing toxicity. The primary objective was 1-year Leukemia-free survival (LFS). In total, 82 patients were enrolled in the study with a median follow up of 19.7 months; donor used were matched sibling in 22, matched unrelated 52 and mismatched unrelated in 8 cases, respectively. LFS at 180-day and 365-day were 87.8% and 81.7%, respectively. Cumulative incidence of relapse at 1 year after allo-HSCT was 14.9% with mean time to relapse of 5.6 months. Also, FT14 regimen provided an excellent safety with nearly absent NRM, no cases of septic death, and no cases of primary graft failure. Our study supports the use of FT14 as effective myeloablative conditioning regimen for AML patients aged 40–65 y in first complete remission, especially in patients for whom busulfan based conditioning regimens poses excessive toxic risks.
- 24 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1176-1181
Open AccessA phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first complete remission
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and efficacy of FT14 conditioning regimen in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in first complete remission.(EudraCT Number:2021-006515-28; Clinical trial number NCT07232953). The study was designed to provide a non-inferior alternative to standard busulfan-containing regimens, which would enable effective transplantation while minimizing toxicity. The primary objective was 1-year Leukemia-free survival (LFS). In total, 82 patients were enrolled in the study with a median follow up of 19.7 months; donor used were matched sibling in 22, matched unrelated 52 and mismatched unrelated in 8 cases, respectively. LFS at 180-day and 365-day were 87.8% and 81.7%, respectively. Cumulative incidence of relapse at 1 year after allo-HSCT was 14.9% with mean time to relapse of 5.6 months. Also, FT14 regimen provided an excellent safety with nearly absent NRM, no cases of septic death, and no cases of primary graft failure. Our study supports the use of FT14 as effective myeloablative conditioning regimen for AML patients aged 40–65 y in first complete remission, especially in patients for whom busulfan based conditioning regimens poses excessive toxic risks.
- Open Access
- 22 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1398-1401
Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study
- 22 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1398-1401
Open AccessTreatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study
- 20 September 2024
- Published by Elsevier in The Lancet Haematology
- Vol. 11 (11) , e830-e838
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial
- 20 September 2024
- Published by Elsevier in The Lancet Haematology
- Vol. 11 (11) , e830-e838
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial
- 17 July 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (10) , 1477-1479
Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project
- 17 July 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (10) , 1477-1479
Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project
- Open Access
- 1 January 2021
- Published by Elsevier in Leukemia Research Reports
- Vol. 15, 100243
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report
- 1 January 2021
- Published by Elsevier in Leukemia Research Reports
- Vol. 15, 100243
Open AccessAcute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report
- Open Access
- 1 September 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (9) , 1814-1822
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi
- 1 September 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (9) , 1814-1822
Open AccessA Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi
- Open Access
- 1 September 2014
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (9) , 1399-1406
Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin
- 1 September 2014
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (9) , 1399-1406
Open AccessMobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin
- Open Access
- 16 November 2012
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 1984
Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial
Abstract 1984
- 16 November 2012
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 1984
Open AccessIntensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial
Abstract 1984